SUMMARY FOR BASIS OF APPROVAL REFERENCE NUMBER:

First Page		Document Content
Bacillus Calmette-Guérin Vaccines Bladder cancer Carcinoma Immunotherapy Carcinoma in situ BCG as a treatment for bladder cancer Transitional cell carcinoma Medicine Tuberculosis Cancer treatments		SUMMARY FOR BASIS OF APPROVAL REFERENCE NUMBER: Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 1,04 MB Share Document on Facebook

	DCIS Ductal Carcinoma In Situ science & experience Elizabeth McLoughlin, ScD DocID: 1sIdd - View Document
	DBCG-retningslinierLobular Carcinoma In Situ (LCISResumé af DBCG’s anbefalinger Formål At sikre alle patienter med LCIS tilbud om optimal udredning, behandling og DocID: 1swAf - View Document
	DBCG-retningslinierDuktalt carcinoma in situ (DCISResumé af DBCG’s anbefalinger Formål At sikre at udredning på mistanke om DCIS og behandling, hvor diagnosen bekræftes, DocID: 1qlQd - View Document
	Tumor Original duffy Size etArticle al DocID: 1ob2H - View Document
	Technical advance Related Commentary, page 401 Cellular and genetic diversity in the progression of in situ human breast DocID: 1nawr - View Document